S5 mutations disrupt RyR1 channel function, influencing both channel activity and gating mechanisms. This impacts the release of calcium and affects muscle contractions, leading to severe muscle ...

BOSTON--(BUSINESS WIRE)--RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma (the “Company” or “RyCarma”), a clinical-stage biotech company developing first-in-class small molecule therapeutics ...

Armgo Pharma is making a fresh start this new year, as the Boston-based biotech announced Tuesday that it will henceforth be known as RyCarma Therapeutics. The new name draws from the company’s nearly ...

BOSTON--(BUSINESS WIRE)--RyCarma Therapeutics, Inc., a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, has ...